In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 mo.
Where this comes from
- Record sourced from PubMed, PMID 38437698.
- Also identified by DOI 10.7326/J24-0004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Maurer MS, Kale P, Fontana M, et al; APOLLO-B Trial Investigators. <b>Patisiran treatment in patients with transthyretin cardiac amyloidosis.</b> N Engl J Med. 2023;389:1553-1565. 37888916.
Medical subject headings
- Amyloid Neuropathies, Familial